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Abstract
Kinetoplastid parasites—trypanosomes and leishmanias—infect millions of humans and
cause economically devastating diseases of livestock, and the few existing drugs have seri-
ous deficiencies. Benzoxaborole-based compounds are very promising potential novel anti-
trypanosomal therapies, with candidates already in human and animal clinical trials. We
investigated the mechanism of action of several benzoxaboroles, including AN7973, an
early candidate for veterinary trypanosomosis. In all kinetoplastids, transcription is polycis-
tronic. Individual mRNA 5’-ends are created by trans splicing of a short leader sequence,
with coupled polyadenylation of the preceding mRNA. Treatment of Trypanosoma brucei
with AN7973 inhibited trans splicing within 1h, as judged by loss of the Y-structure splicing
intermediate, reduced levels of mRNA, and accumulation of peri-nuclear granules. Methyla-
tion of the spliced leader precursor RNA was not affected, but more prolonged AN7973
treatment caused an increase in S-adenosyl methionine and methylated lysine. Together,
the results indicate that mRNA processing is a primary target of AN7973. Polyadenylation is
required for kinetoplastid trans splicing, and the EC50 for AN7973 in T. brucei was increased
three-fold by over-expression of the T. brucei cleavage and polyadenylation factor CPSF3,
identifying CPSF3 as a potential molecular target. Molecular modeling results suggested
that inhibition of CPSF3 by AN7973 is feasible. Our results thus chemically validate mRNA
processing as a viable drug target in trypanosomes. Several other benzoxaboroles showed
metabolomic and splicing effects that were similar to those of AN7973, identifying splicing
inhibition as a common mode of action and suggesting that it might be linked to subsequent
changes in methylated metabolites. Granule formation, splicing inhibition and resistance
after CPSF3 expression did not, however, always correlate and prolonged selection of
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Author summary
Trypanosomes and leishmanias infect millions of humans and cause economically devas-
tating diseases of livestock; the few existing drugs have serious deficiencies. Trypanosomo-
sis of cattle caused by Trypanosoma congolense and Trypanosoma vivax, is a serious
problem in Africa because cattle are used not only for food but also for traction, and new
drugs are needed. A single injection of the benzoxaborole compound AN7973 cured T.
congolense infection in cattle and goats. Although slightly lower effectiveness against T.
vivax precludes development of AN7973 as a commercially viable treatment against cattle
trypanosomosis, it could still have potential for diseases caused by other trypanosomes.
We used a large range of methods to find out how AN7973 kills trypanosomes, and com-
pared it with other benzoxaboroles. AN7973 and some of the other compounds had effects
on parasite metabolism that resembled those previously seen for a benzoxaborole that is
being tested for human sleeping sickness. The most rapid effect of AN7973, however, was
on processing of trypanosome mRNA. As a consequence, amounts of mRNA decreased
and synthesis of proteins stopped. We conclude that AN7973 and some other benzoxabor-
oles kill trypanosomes by stopping gene expression.
Introduction
Kinetoplastid protists cause severe human diseases affecting millions of people. Trypanosoma
cruzi causes Chagas disease in South America, and various Leishmania species cause a spec-
trum of diseases throughout the tropics. Salivarian trypanosomes, the subject of this study,
cause sleeping sickness in humans and economically important diseases in cattle, horses and
camels [1–3]. Approximately 70 million people, living in sub- Saharan Africa, are estimated to
be at risk of contracting human African trypanosomosis, which is caused by Trypanosoma bru-
cei subspecies [4, 5]. As a result of sustained international activities to control the disease [4–
6], less than 3000 cases were reported in 2016 (http://www.who.int/trypanosomiasis_african/
en/). Trypanosomosis in cattle, caused by infection with Trypanosoma congolense, Trypano-
soma vivax and, to a lesser extent, T. brucei, is in contrast a major problem, with wide-reaching
effects on human well-being: cattle are used not only as a source of milk and meat, but also for
traction. Elimination of cattle trypanosomosis could create economic benefits estimated at
nearly 2.5 billion US$ per year [2]. Within Africa, trypanosomosis is transmitted by tsetse flies,
but outside Africa, variants of T. brucei are transmitted venereally or by biting flies, and T.
vivax can also be transmitted non cyclically by non-tsetse biting flies with massive economic
losses affecting draught and milk animals from Argentina to the Philippines [7].
Control of cattle trypanosomosis currently relies on reducing the tsetse population by
means of traps and insecticidal dips, together with treatment as required. The most popular
treatment is with the diamidine diminazene aceturate (Berenil), the alternative being the
DNA-intercalating molecule isometamidium [3]. Suramin is also sometimes used [3]. Devel-
opment of new animal therapeutics is constrained by the need for cure after a single intramus-
cular injection [3].
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In the last ten years, benzoxaboroles have generated considerable excitement for antimicro-
bial and other applications. Benzoxaboroles have a range of known effects. For example, they
are able to bind cis-diols, such as those found in sugars, yielding stable spiro complexes [8].
This activity is the basis of the mode of action of the antifungal drug Tavaborole (AN2690) [9],
which binds to the editing site of leucyl tRNA synthetase [10]. Other oxaboroles inhibit bacte-
rial leucyl tRNA synthetases by the same mechanism [11–13]. Other benzoxaborole classes
interact with ATP-binding pockets, but with different modes of binding. Crisaborole,
approved for the treatment of atopic dermatitis [14, 15], selectively inhibits phosphodiesterase
PDE4, with the oxaborale oxygen atoms coordinating the zinc and magnesium ions within the
active site [16]. The aminomethylphenoxy benzoxaboroles inhibit Rho-activated protein
kinases through hydrogen bond interactions with the hinge region of the protein and the ami-
nomethyl group interacting with the magnesium/ATP-interacting aspartic acid [17].
The first trypanocidal oxaboroles to be described were the oxaborole 6-carboxamides [18,
19]. Acoziborole (trade name of SCYX-7158 or AN5568, 1) [20] is orally available and can
cross the blood brain barrier [18]; it is now in phase IIb/III clinical trials for sleeping sickness
(see https://www.dndi.org/diseases-projects/portfolio/). AN7973 (Fig 1), the main subject of
this paper, is efficacious against T. congolense and T. brucei and was considered as a candidate
for treatment of cattle trypanosomosis, but was later replaced by AN11736 (Fig 1), which can
achieve single-dose cure of both T. congolense and T. vivax infection in cattle [21].
At present, not enough is known about structure-activity relationships in benzoxaboroles
to enable predictions to be made about their modes of action. Jones et al. [22] obtained T. bru-
cei lines with 4-5-fold resistance to AN2965 (Fig 1, named oxaborole-1 in their paper). They
observed numerous single nucleotide polymorphisms (SNPs), genome rearrangements and
amplifications in the resistant lines. Affinity purification with a benzoxaborole column yielded
14 proteins that bound specifically, but since none of these was affected in the resistant
mutants, there was no clear indication as to which might be relevant to benzoxaborole action
[22]. Aminomethyl phenoxyl benzoxaboroles such as AN3056 are sequentially activated to an
active carboxylic acid form by serum and intracellular enzymes [23].
Various oxaboroles are being considered for treatment of apicomplexan parasites; and
AN13762 (Fig 1) is in development [24, 25]. Plasmodium and Toxoplasma that were resistant
to AN3661 (Fig 1) had mutations in the cleavage and polyadenylation factor CPSF3 [26, 27],
which is implicated in 3’ cleavage of mRNA precursors prior to polyadenylation [28]. The two
zinc ions of CPSF3 are thought to interact with phosphate [28]. In silico molecular docking of
AN3661 suggested that the boron atom occupies the position of the cleavage site phosphate of
the mRNA substrate, with one hydroxyl group interacting with a zinc atom in the catalytic site
—similar to binding of other benzoxaboroles to the bimetal centers of beta-lactamase and
phosphodiesterase-4 [26, 27]. Introduction of resistance mutations—which were all in or near
the active site—into susceptible parasites resulted in compound resistance. These results, com-
bined with the loss of transcripts for three trophozolite-expressed genes in treated parasites,
suggest that AN3661 inhibits mRNA polyadenylation through its interaction with CPSF3 [26,
27].
In trypanosomes, transcription of mRNAs is polycistronic. Individual mRNA 5’-ends are
created co-transcriptionally by trans splicing of a 39nt leader sequence (SL) [29–31]. Trans
splicing is spatially and mechanistically coupled to polyadenylation of the preceding mRNA.
Polyadenylation sites are dictated by the positions of trans-splicing sites [32–35], RNAi-medi-
ated depletion of polyadenylation factors inhibits trans splicing [36, 37], and disruption of
splicing stops polyadenylation [32–35]. The spliced leader precursor RNA (SLRNA) is 139 nt
long and is synthesised by RNA polymerase II [38] from approximately 200 tandemly repeated
genes [39]. Unlike protein-coding genes, each SLRNA gene has its own promoter [40–42]. The
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SLRNA cap and the following four nucleotides are methylated [43–46]. Inhibition of SLRNA
methylation using S-adenosyl-L-homocysteine or Sinefungin prevents splicing [47, 48]. This
results in loss of mRNA from the cells by the normal mechanisms of mRNA turnover [49]. It
has recently been shown that an accumulation of numerous metabolites, including S-adenosyl-
methionine, occurs in trypanosomes treated with Sinefungin, and a similar profile was identi-
fied in trypanosomes treated with acoziborole [50].
We here describe studies to discover molecular targets of several anti-trypanosomal ben-
zoxaboroles. Our work concentrated on AN7973 (Fig 1), which is orally active and was the
DNDi back-up for SCYX-7158/AN5568 for the treatment of human African trypanosomosis.
We undertook a comprehensive analysis, including resistance generation and characterisation
of morphology, metabolomes, macromolecular biosynthesis and molecular modeling.
Results
Anti-trypanosomal activities of AN7973
AN7973 (Fig 1) was selected as a candidate veterinary drug from a range of 7-carboxamido-
benzoxaboroles structurally similar to AN5568. The selection of AN7973 was based on its in
vitro potency against T. congolense (S1 Table, sheet 1) and its ability to cure T. congolense-
infected mice with a single 10mg/kg i.p. dose (S1 Table, sheet 3).T. congolense-infected goats
were also cured when AN7973 was administered as a single bolus dose injection of 10 mg/kg,
but for T. vivax-infected goats, two intramuscular injections of 10 mg/kg were required (S1
Table, sheet 3). Testing in cattle was done using T. vivax and T. congolense isolates that were
resistant to maximum dosages of diminazene (7 mg/kg) and isometamidium (1 mg/kg). A
Fig 1. Structures of benzoxaboroles studied in this paper. The benzoxaborole scaffold is in cyan.
https://doi.org/10.1371/journal.ppat.1007315.g001
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single 10 mg/kg intramuscular injection of AN7973 cured 3/3 cattle of T. congolense infection,
but two 10 mg/kg injections of AN7973 cured only one out of two T. vivax infections and a sin-
gle injection failed to cure 3 animals (S1 Table, sheet 3). This meant that AN7973 would be
inappropriate for field use [3]. The reduced efficacy of AN7973 against T. vivax might have
been a consequence of weaker intrinsic potency: the ex vivo EC50 against T. vivax was 215 nM,
as against an in vitro EC50 of 84 nM for T. congolense (S1 Table, sheet 1). The latter value is sim-
ilar to the results for T. brucei (20–80 nM, S1 Table).
The lack of single-dose cattle efficacy at 10mg/kg i.m. against T. vivax precluded develop-
ment of AN7973 as a commercially viable treatment against cattle trypanosomosis, but it could
still have potential for diseases caused by other salivarian trypanosomes.
Resistance selection, cell cycle and protein synthesis
One of the most direct strategies to identify the targets of antimicrobial drugs is selection of
resistant mutants. We therefore attempted to select parasites resistant to AN7973 using an
over-expression library [51]. The level of resistance obtained was very modest—less than
2-fold (S2 Table, sheet 1) and in the two lines that we obtained, the over-expression plasmids
did not contain an in-frame coding sequence. We therefore sequenced their genomic DNA.
As previously observed for trypanosomes that were mildly resistant to AN2965 [22] we found
numerous single nucleotide polymorphisms, amplifications and deletions (summarized in S2
Table, details in S3 and S4 Tables). The large number of genes affected made it impossible to
pinpoint any particular pathway as being relevant to resistance.
Examination of parasite morphology can reveal defects in DNA synthesis, cell cycle regula-
tion, cell motility and protein trafficking, each of which can ultimately cause parasite death.
For example, Jones et al. saw accumulation of parasites in the G2 phase of the cell cycle after
AN2965 treatment [22]. Treatment of trypanosomes with AN7973 with 10x EC50 for 7h caused
growth arrest (Fig 2A), but no obvious changes in parasite morphology or motility and no sig-
nificant changes in the proportions of cells in different stages of the cell cycle (Fig 2B). These
results suggest that AN7973 does not interfere directly with DNA synthesis, cell motility, or
protein trafficking.
Amino-acyl tRNA synthetase inhibition is a known mode of action of several benzoxabor-
oles, and inhibition of tRNA synthetase should result in cessation of protein synthesis. We
therefore measured this in AN7973-treated trypanosomes by pulse labelling with [35S]-methio-
nine followed by denaturing polyacrylamide gel electrophoresis and autoradiography. Inhibi-
tion of protein synthesis (Fig 2C) was clear, but some prominent protein bands were affected
more than others (compare bands labeled a and b). The kinetics of the inhibition, combined
with apparent selectivity for particular proteins, suggested that protein synthesis was not a pri-
mary target of AN7973, but might be inhibited in a secondary fashion.
AN7973 inhibits mRNA processing
Loss of protein synthesis could be caused by loss of mRNA. For example, if mRNA synthesis
were inhibited, the pattern in Fig 2C would be explained if the mRNA encoding protein "b"
were less stable than that encoding protein "a". Loss of mRNA could be caused by inhibition of
either RNA transcription or processing. To investigate this possible mechanism, we incubated
cells with AN7973, prepared RNA, and hybridised Northern blots with a probe that detects the
spliced leader SL. This probe detects all processed mRNAs, as well as the ~139nt precursor,
called SLRNA, that donates the SL. Incubation with AN7973 for 9h had little or no effect on
the total amount of rRNA, as judged by methylene blue staining (Fig 3A) but caused progres-
sive loss of spliced mRNA (Fig 3B). In contrast, the levels of the SLRNA remained roughly
The trypanocidal benzoxaborole AN7973 inhibits trypanosome mRNA processing
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constant (Fig 3B). We therefore suspected that AN7973 was inhibiting mRNA processing. To
test this we re-hybridised the blot with a probe that detects beta-tubulin. The tubulin genes are
arranged in alternating alpha-beta tandem repeats, and splicing inhibition through heat shock
[52] or Sinefungin treatment [47] leads to accumulation of partially processed beta-alpha
dimers and multimers. Partially processed tubulin mRNAs were indeed detected within an
hour of AN7973 application (Fig 3C). This result showed that after AN7973 addition, tran-
scription of protein-coding genes continued but mRNA processing was impaired. At later
time points, the tubulin mRNAs disappeared, suggesting that the failure in processing was
complete. (Most measurements suggest that the tubulin mRNAs have half-lives of about half
an hour [53].)
As noted above, after 1h AN7973 treatment, the level of SLRNA was not much changed.
This is somewhat counter-intuitive, since one might expect processing inhibition to lead to a
build-up of SLRNA. However, RNAi that targets splicing or polyadenylation factors rarely
causes SLRNA increases of more than 2-fold [37, 54, 55]. The reason is that SLRNA synthesis is
balanced by degradation. Thus when Actinomycin D (Act D) is used to inhibit transcription,
Fig 2. Effects of AN7973 on the cell cycle and protein synthesis. A) Cumulative growth curve for bloodstream-form
trypanosomes incubated with and without AN7973. Results are arithmetic mean ± standard deviation for three
replicates. B) Cell cycle analysis by microscopy. The percentages of cells with different numbers of nuclei and
kinetoplasts are shown. C) Effect on protein synthesis. 5x106 Cells were incubated with AN7973 (10x EC50) for various
times, then (after washing and 15-min pre-incubation) with [35S]-methionine for 30 min. Proteins were separated by
SDS-PAGE and radioactive incorporation was assessed by autoradiography. The Coomassie-stained gel is shown as a
loading control. Two prominent protein bands showing different effects of AN7973 are indicated as "a" and "b". All
lanes are from the same gel and exposure; the gaps between the lanes are present because identical results for two
partially resistant lines (also treated at 10x EC50) have been deleted.
https://doi.org/10.1371/journal.ppat.1007315.g002
Fig 3. AN7973 affects mRNA processing. A) Trypanosomes were incubated with AN7973 for different times (0–9 hours). RNA was subjected to denaturing
agarose gel electrophoresis, blotted, and detected using radioactive probes. This panel shows Methylene blue-stained gel showing equal loading of total RNA. The
three prominent bands are rRNA. B) As (A), blot probed with a [32P]-end-labelled probe complementary to the spliced leader. The signals representing the ~140nt
SLRNA and mature mRNAs are indicated. The cluster of bands around 2 kb probably represent the abundant mRNAs encoding the Variant Surface Glycoprotein,
alpha and beta tubulin (both ~1.9 kb including 100nt poly(A)), and EF-1 alpha (1.8 kb) [91]. C) The blot from (B) was stripped then incubated with a beta-tubulin
probe. Shadows from the SL probe remain. The positions of monomer, dimer and multimers from the tubulin repeats are indicated. D) The effect of AN7973 is
not due to inhibition of SLRNA synthesis. Trypanosomes were treated either with AN7973 for 1h, or with Actinomycin D for 30 min, or with AN7973 followed by
Actinomycin D, as indicated above the lanes. The lower panel is the rRNA loading control.
https://doi.org/10.1371/journal.ppat.1007315.g003
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SLRNA disappears within 30 min even though no new precursors are available for splicing
[56]. Fig 3D compares the effects of AN7973 with those of Act D treatment. As expected, 30
min Act D resulted in SLRNA loss whereas AN7973 had no effect. Moreover, if Act D was
added after a one-hour AN7973 treatment, SLRNA again disappeared within 30 min—whereas
SLRNA was still visible after 9h in the presence of AN7973. We concluded that treatment of
the cells with AN7973 for only one hour inhibited mRNA processing but did not prevent syn-
thesis of SLRNA.
Inhibition of procyclic trypanosome mRNA processing by RNAi targeting polyadenylation
factors causes growth arrest within 3 days, followed by cell death [37, 54]. These delays in
observing effects are explained by the fact that the targeted proteins remain detectable (see e.g.
[55]). Processing inhibition can therefore easily explain killing of trypanosomes by AN7973.
mRNA processing inhibition by AN7973 is not due to loss of cap
methylation
The only small molecule currently known to inhibit kinetoplastid mRNA processing in vivo is
the S-adenosyl methionine analogue Sinefungin, which is a general methylation inhibitor [57].
Chemical inhibition of spliced leader methylation prevents trans splicing in a permeabilised
cell system [48], and Sinefungin does the same in vivo [47]. Since we already knew that
AN5568 caused increases in methylated intermediates [50], we wondered whether splicing
inhibition by AN7973 was also caused by inhibition of spliced leader methylation. We used
primer extension to assess the amount and methylation status of SLRNA. At the same time, we
assayed the level of the 2’-5’ branched "Y-structure" splicing product (Fig 4A). cDNA synthesis
was primed by a 5’-labelled oligonucleotide that is complementary to a region towards the 3’
end of the SLRNA (black arrows in Fig 4B). The products from full-length SLRNA form a small
ladder, because 5’ methylation partially blocks reverse transcriptase, while the Y-structure
trans splicing intermediate gives a product of 87nt (Fig 4B). These products are seen in Fig 4C,
lane 1. As expected, incubation with the methylation inhibitor Sinefungin for 30 min abolished
the multiple bands caused by cap methylation, with cDNA synthesis extending cleanly to the 5’
end of the SLRNA (Fig 4C, lane 4, arrowhead); at the same time, the signal from the Y structure
was decreased. The concentration of Sinefungin used, 2 μg/mL, is 4000 times the EC50. This is
the standard concentration in these types of experiments and was chosen in order to prevent
cap methylation within about 10 min [58].
Importantly, AN7973 (10x EC50) had no effect on the pattern of bands from the SLRNA,
showing that cap methylation was not affected (Fig 4C). In contrast, Y-structure formation
was clearly decreased (Fig 4C, lanes 2 and 3). The combined results so far thus showed that
AN7973 acts specifically on splicing, not on production of mature splicing-competent SLRNA.
Quantitation of four independent experiments showed that after 30 min, the effect of AN7973
was already significant (p<0.0005, S3A Fig). Remarkably, considering the differences in the
doses used, a 2-h incubation with AN7973 inhibited Y-structure formation to the same extent
as a 30-min incubation with Sinefungin (Fig 4D).
Although the effect of AN7973 on splicing was quite rapid, we nevertheless had to consider
the possibility that it was secondary to inhibition of some other process. Apart from Sinefun-
gin, the only treatment that was previously shown to cause accumulation of tubulin precursors
within 30 min was severe heat shock [52, 59], but the mechanism is unknown and there are
numerous other effects including general translation arrest [59] and transcription inhibition
[60]. To find out whether trans splicing inhibition was a general feature of parasites stressed
through addition of trypanocidal or trypanostatic drugs, we measured Y structure abundance
in cells treated with DFMO, diminazene aceturate, pentamidine or suramin, all at 10x EC50.
The trypanocidal benzoxaborole AN7973 inhibits trypanosome mRNA processing
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007315 September 25, 2018 8 / 33
Fig 4. Effect of AN7973 on trans-splicing. A) Schematic representation of the splicing reaction. SLRNA and Y structure during primer
extension experiments. SLRNA is represented with various colours; red is the cap4 region, green is the spliced leader (SL), blue is the SL
intron. The pre-mRNA is shown with a grey intergenic region and a magenta portion that represents the 5’ end of a mature mRNA. The 5’
and 3’ ends of each RNA are indicated. During trans splicing, the SL intron forms a branched "Y" structure with the 2’ hydroxyl of an
adenosine located 5’ to the polypyrimidine tract that is recognised by the splicing machinery. Meanwhile the SL is trans spliced to the 5’-
end of the mRNA. B) Schematic representation of the primer extension assay. The 5’-end labelled oligonucleotide primer hybridises
towards the 3’ end of the SLRNA. Reverse transcription on the intact SLRNA extends (dashed line) towards the 5’ end but terminates upon
encountering the methylated residues of cap4. In the Y structure, the primer extends (dashed line) until the branch point, giving an 87nt
product. C) Typical result from a primer extension experiment illustrated in (B). A primer complementary to the U3 snRNA was used as a
control. Lane 1 (0’) shows the result from trypanosomes that were treated with DMSO only. Lanes 2 and 3 show the results from
trypanosomes treated with AN7973 for 30 min and 60 min, and lane 4 is the result for 30 min Sinefungin. The arrowhead shows the
primer extension product from unmethylated SLRNA. D) Quantification from several independent tests of AN7973 treatment; the ratio
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No significant inhibition of Y-structure formation was observed (Fig 4E–4H, S3 Fig). This
result demonstrated conclusively that splicing inhibition is not a general side-effect of growth
inhibition. The effect of AN7973 on splicing therefore indicates a specific mechanism.
Metabolic effects of AN7973
Another possible cause of splicing inhibition might be severe metabolic disruption. The fact
that the parasites retained normal motility for several hours indicated that there were no
immediate effects upon ATP generation, and we already knew that both mRNA transcription
and SLRNA modification were unaffected. Analysis of the metabolome after 5h AN7973 treat-
ment revealed, however, that the main effects were—as with AN5568—related to methylation,
with substantial increases in S-adenosylmethionine (SAM) methyl thioadenosine (MTA),
methyl lysine (ML), dimethyl lysine (2ML), trimethyl lysine (3ML) and acetyl lysine (AL) (Fig
5; S5 Table). SAM is a methyl donor and it has been shown that the methyl groups on the
methylated lysines are derived from methionine [50]. It therefore seemed worthwhile to find
out whether other anti-trypanosomal benzoxaboroles had similar effects.
We started with a panel of 30 compounds. These were tested in vitro against T. brucei and
T. congolense (S2 Fig, S1 Table) and metabolic effects were also assessed (S6 Table). We then
selected various compounds based on potency, the time taken to see an effect (S3 Fig), and the
effects on methylated amino acids, SAM and MTA (S6 Table). Nearly all of the chosen com-
pounds had EC50s in the low nM range (Fig 6). The notable exception was AN3661 (Fig 1), the
anti-malarial lead compound that targets CPSF3 [26, 27]: its EC50 for bloodstream-form try-
panosomes was at least 20 times higher than that of AN7973. At a concentration of 5x the EC50
determined at 48h, most of the compounds acted within 6-8h (S3 Fig, S1 Table). The veteri-
nary drug candidate AN11736 kills the parasites more slowly because it requires processing for
full activity (Giordani et al., manuscript in preparation). Results for treatment of T. brucei with
the selected compounds are shown in Fig 5. There were no discernable structure-activity rela-
tionships for EC50, time to kill, or the SAM/MTA effect, but most of the oxaboroles that
induced a SAM/MTA pattern were faster killing.
Relationship between splicing inhibition and SAM/MTA accumulation
To investigate the possible link between splicing inhibition and the methylated metabolites, we
measured the effects of the chosen compounds on splicing. We also included AN2965 (Fig 1),
the compound whose mode of action had been investigated previously [22], and the antimalar-
ial candidate AN13762 (Fig 1, compound 46 in [25]). Initial triplicate measurements (Fig 7A,
experiment 1) gave reproducible results for most of the compounds; repeat assays for three
that had given ambiguous results confirmed that they gave substantially less splicing inhibition
than AN7973 (Fig 7, experiment 2 and S4A Fig). The clear processing inhibitors included the
antimalarial candidate AN13762 (compound 46 in [25]); the EC50 of this compound for try-
panosomes in the 3-day assay was 4 times higher than that for P. falciparum. Overall, there was
a remarkably good correlation between splicing inhibition and the average increase in SAM
and MTA (Fig 7B); only two compounds did not conform to the overall pattern. A caveat is
between Y structure and the U3 signal is shown. # indicates the number of data points used. Sinefungin results were taken only from
experiments that included AN7973 on the same gel. The central line is the median, and boxes extend from the 25th to the 75th quartile.
The whiskers extend to the most extreme data point that is no more than 1.5 times the inter-quartile range. Other points are outliers.
Details for our initial experiments are in S1A and S1B Fig. After only 30 min incubation with AN7973, the difference between treated and
untreated cells was significant using a one-way ANOVA. E-H) Trypanosomes were incubated with 10x EC50 of various known anti-
trypanosomal drugs for 1h or 2h, then splicing was assayed. The % Y structure (relative to U3) is shown (individual points, plus mean and
standard deviation). The 95% confidence intervals are shown in S1C–S1F Fig.
https://doi.org/10.1371/journal.ppat.1007315.g004
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Fig 5. Effects of benzoxaboroles on the metabolome. Fold increases are shown for selected metabolites, relative to
untreated cells (mean and standard deviation). The numerical data are in S6 Table. SAM: S-adenosylmethionine;
MTA: methylthioadenosine; ML: methyllysine; 2ML: dimethyllysine; 3ML: trimethyllysine; AL: acetyllysine.
https://doi.org/10.1371/journal.ppat.1007315.g005
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that AN11736 is slow acting, and was used at low doses given its extreme potency, so it is possi-
ble that splicing inhibition by AN11736 might be seen upon more prolonged incubation.
Why could splicing inhibition and S-adenosyl methionine-related metabolites be linked?
We could think of two explanations. First, transcription and processing of the SLRNA genes
absorbs substantial cellular resources, since the cell needs to make at least 10,000 SLRNAs per
hour [53]. It was possible that after 6-8h (the time of most metabolome measurements), there
might have been some feedback inhibition of transcription that led to a decreased methylation
requirement. Second, loss of mRNA production leads to loss of unstable mRNAs. If the protein
encoded by an unstable mRNA has a high turnover rate, then that protein will disappear; and
if that protein is a metabolic enzyme, its substrates will accumulate. This too could have led to
metabolic changes as we noted.
To address the second hypothesis, we directly measured the effect of mRNA synthesis inhi-
bition on the metabolome, using Actinomycin D (10 μg/mL) for 6h. Interestingly, there were
again large increases in the amounts of methylated amino acids and significant (but smaller)
increases in SAM and MTA as well (Fig 5). Comparison with the well-characterised effects of
AN5568 revealed a clear correlation (Fig 7C, S7 Table). These results suggest that the increases
in methylated and acetylated lysine—and perhaps also in SAM and MTA—that were seen after
treatment with benzoxaboroles could indeed be an indirect consequence of loss of mRNA.
In vitro splicing
As an alternative way to find out whether the effect of AN7973 on mRNA processing was
direct or indirect, we measured trans splicing in permeabilised procyclic-form trypanosomes
[48]. (Equivalent assays are not established for bloodstream forms.) As for most benzoxabor-
oles that have been tested (Fig 6, S1 Table) the EC50 of AN7973 for procyclic forms was 5–10
times higher than that for bloodstream forms. Treatment with 10x EC50 clearly inhibited splic-
ing in procyclic forms, with 70% loss of Y structure after 2h (S4B and S4C Fig).
To test splicing in vitro, procyclic trypanosomes were permeablised with lysolecithin, pre-
incubated with AN7973 or DMSO, then transcription was allowed to proceed for 10 min in
the presence of [alpha-32P]-UTP [61]. RNA was separated on 7% polyacrylamide-urea gels and
visualized by autoradiography. Under these conditions, the SL intron is visible as a ~100nt spe-
cies, which disappears if incubation is continued for a further 20 min [61]; it is also not made if
cap methylation is inhibited by S-adenosyl homocysteine [48].
Fig 6. EC50s of selected benzoxaboroles for salivarian trypanosomes. The graph shows EC50s against T. brucei (in
vitro, 48h assay for bloodstream forms, 72h for procyclic forms) and for selected compounds, also against T. congolense
(in vitro) and T. vivax (ex vivo). Details for all tested compounds are in S1 Table.
https://doi.org/10.1371/journal.ppat.1007315.g006
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Fig 7. Relationship between trans splicing inhibition and methylation changes. A) Trypanosomes were incubated
with 10x EC50 of various compounds for 2h, then splicing was assayed as in Fig 4. The % Y structure (relative to the U3
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We do not know the intracellular concentration of AN7973, and in the in vitro transcription
reaction the density of permeabilised parasites is 1000 times higher than in the experiments
with cultures. For the in vitro assays we therefore chose to use a concentration of 100 μM (500x
the EC50), which gives a AN7973:parasite ratio that is equivalent to the ratio at 5x EC50. This
treatment reproducibly prevented formation of the Y structure without preventing transcrip-
tion of SLRNA or smaller RNAs (Fig 8). An additional band (arrowhead), which appeared in
the presence of AN7973 and was slightly shorter than SLRNA, might be a 3’ degradation prod-
uct that was previously described [48]. AN7973 also reproducibly inhibited labeling of RNAs
longer than 500nt (indicated by a question mark). These RNAs are thought to include mRNAs
and rRNA [62], and the inhibition could either be a consequence of trans splicing inhibition
or another effect of AN7973. In future it would be interesting to repeat these studies at a variety
of concentrations and with other benzoxaboroles.
Benzoxaborole treatment induces formation of stress granules
When trypanosomes are stressed by heat shock or starvation, their mRNAs accumulate in
RNA-protein particles called stress granules containing a helicase, DHH1 [63]. Generally, these
are throughout the cytoplasm, but after treatments that inhibit splicing, they transiently cluster
around the nuclear envelope [64]. To find out whether AN7973 had the same effect we followed
localization of YFP-tagged DHH1 in treated cells (Fig 9; the YFP signal is coloured magenta). A
few granules were seen in untreated cells (Fig 9A) but after 30 min Sinefungin treatment, the
nuclear periphery granule pattern was clear (Fig 9B). AN7973 also induced formation of peri-
nuclear granules in a subset of cells (Fig 9C). However, when the remaining compounds were
tested (S5 Fig, S6 Fig, S7 Fig) we observed no correlation between peri-nuclear granule forma-
tion and Y structure inhibition (Fig 9D). This may partly be explained by the transient nature of
the perinuclear localization, but the clear perinuclear granule formation after AN11736 treat-
ment also suggests that the pattern can be caused by stresses other than splicing inhibition. We
concluded that without careful time-course studies, this assay could not be used to distinguish
between specific splicing effects and more general stress responses.
Ectopic expression of CPSF3 results in resistance to benzoxaborole splicing
inhibitors
To try to identify possible targets implicated in mRNA processing, we re-examined the
genomes of our partially-resistant lines (S2–S4 Tables). Since loss of polyadenylation stops
splicing [36, 37], we looked for changes in genes associated with both processes. No mutations
of the U snRNAs were found. A missense mutation was found in the Tb927.10.9660 open
reading frame encoding a putative CRN/SYF3; this protein co-purified with the PRP19 com-
plex, but did not co-sediment with the complex on a sucrose gradient [65]; its function is thus
unclear. The Sm complex forms the core of spliceosomal snRNPs, and our two cell lines that
had been selected in AN7973 both had 1–2 extra copies of the genes encoding four out of the
seven components: Sm-B, Sm-E, Sm-F and Sm-G. The other three genes were, however, not
control) is shown. Results are shown for one experiment (experiment 1) with a full compound set and for a second
experiment with selected compounds. A time course for the second experiment is shown in S4A Fig. B) The mean
increase in SAM and MTA after treatment with each compound is plotted on the y-axis; the x-axis shows mean and
standard deviation of the % Y-structure remaining (data for experiment 1 in (A)). The AN numbers are colour-coded
to indicate the time of incubation prior to metabolome analysis. C. Metabolite changes after AN5568 or Act D
treatment (both 5h). Each point represents a metabolite; data are in S7 Table. Orange: significantly affected by
Actinomycin D; cyan: significantly affected by AN5568; purple: significantly affected by both treatments. Labelled
metabolites are: 1- Glutathione disulfide; 2- Lys-Val-Pro; 3- N6,N6,N6-Trimethyl-L-lysine; 4- N6-Acetyl-L-lysine.
https://doi.org/10.1371/journal.ppat.1007315.g007
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amplified. After selection of proteins on an oxaborole affinity column, Jones et al. found
enrichment of RBSR1 (Tb927.9.6870), a protein with an SR-domain that is potentially involved
in splicing, and of the U2 splicing auxiliary factor (U2AF35, Tb927.10.3200) [22]. Our resistant
lines had no changes in RBSR1 or U2AF35.
In P. falciparum and T. gondii, mutations in CPSF3 gave resistance to AN3661 [26, 27].
Moreover, in one of their AN2965 resistant lines, Jones et al. [22] observed a two-fold amplifi-
cation of the gene encoding CPSF3 (Tb927.4.1340; also designated CPSF73); and AN2965 was
a strong inhibitor of splicing (Fig 7A). We therefore compared the T. brucei sequence with
those of Plasmodium and humans, concentrating on the residues that were mutated in
AN3661-resistant Apicomplexa. H36 and Y408 of the P. falciparum sequence were mutated in
Fig 8. In vitro splicing assay. Permeablised procyclic-form trypanosomes (2.5 x 108 / reaction) were incubated for 2
min in the presence of DMSO or AN7973, and then for 10 min in the presence of alpha-32P-UTP. Newly-made RNA
was analysed by denaturing gel electrophoresis and autoradiography. The full-length SLRNA (~140nt) and the de-
branched SLRNA intron (~100 nt) are indicated.
https://doi.org/10.1371/journal.ppat.1007315.g008
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AN3661-resistant lines but are retained as H and Y the human and trypanosome sequences
(S8 Fig). The remaining important Plasmodium residues, however, are already different in try-
panosomes. Y252 (mutated to C for AN3661 resistance) is N in T. brucei; T406 (mutated to I)
is A; T409 (mutated to A) is C; and D470 (mutated to N) is already N in T. brucei (S8 Fig).
From these changes alone one could predict that trypanosomes would be quite resistant to
AN3661—as is indeed the case (S1 Fig). Although AN3661 did inhibit trypanosome mRNA
processing and give a SAM/MTA effect, the concentrations used were 10–20 times higher than
for AN7973 (S1 Table).
To test the role of CPSF3 we first attempted to make the equivalent of the Y408S mutation
in trypanosomes by homologous gene replacement. Interestingly, although the transfections
yielded several transgenic clones, none had the mutation. This, together with the fact that nei-
ther we nor Jones et al. [22] found the mutation after resistance selection, suggests that in the
context of the trypanosome sequence, the Y408S equivalent (Y383S in the T. brucei sequence,
S8 Fig) results in an unacceptable decrease in CPSF3 activity. If so, the result suggests either
that the mutant CPSF3 has dominant-negative effects, or that CPSF3 is present in limiting
amounts such that mutation of one gene copy results in haplo-insufficiency.
Fig 9. Effects of benzoxaborole treatment on formation of YFP-DHH1 granules. A-C) Bloodstream-form trypanosomes with one DHH1
gene tagged in situ were washed with PBS, fixed with formaldehyde, then allowed to adhere to glass slides before imaging to detect YFP-
tagged DHH1 (magenta) and DNA (cyan). Cells were (A) untreated, (B) incubated with Sinefungin (1μg/mL 30 min), or (C) treated with
AN7973 (230 nM, 2h). D) Results for all tested oxaboroles. The average percentages of cells with clear peri-nuclear granules are plotted on
the y-axis and the % Y-structure is on the x-axis. Times to show an effect on growth are as in Fig 6B. Results for the three replicate
experiments are in S5 Fig and typical fields are shown in S6 and S7 Figs.
https://doi.org/10.1371/journal.ppat.1007315.g009
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We next assessed how the differences between T. brucei and P. falciparum CPSF3 sequences
would affect protein conformational dynamics. To do this we investigated a homology model
of CPSF3 by elastic network normal mode analysis (S9A and S9B Fig), and found a relative
rotational breathing motion of the domains (S9C Fig). Interestingly, in the model, many resi-
dues associated with AN3661 resistance, such as Y408 and N252 (P. falciparum numbering)
were found to line the cleft between the breathing domains. Relative domain rotation might
thus be able to enhance the accessibility of the binding site. Thus, mutations associated with
AN3661 resistance might affect the conformational dynamics of the enzyme, the accessibility
of the active site and the stability of the interdomain contacts.
As an alternative to mutation, we inducibly over-expressed RBSR1, U2AF35 and CPSF3 in
bloodstream forms, as C-terminally myc-tagged versions. Expression of RBSR1-myc and
U2AF35-myc (S10A Fig) did not affect the EC50 of AN7973. In contrast, expression of
CPSF3-myc caused at least 3-fold increases in the EC50s of four tested benzoxaboroles, includ-
ing AN7973 (Fig 10, S10B Fig, S8 Table). Statistically significant increases of 2-fold or more
were also seen for several other benzoxaboroles (Fig 10, S10B Fig, S8 Table) and there was a
moderate correlation with Y-structure inhibition (Fig 10B). This suggests that the effective
Fig 10. Ectopic expression of myc-tagged CPSF3 causes mild resistance to some benzoxaboroles. A) Expression of
myc-CPSF3 in three independent cloned cell lines that were used for the assays. Expression was induced by
tetracycline. Tryparedoxin peroxidase (TxNPx) served as a loading control. B) Correlation between the effect of myc-
CPSF3 induction and the extent of Y-structure inhibition in the splicing assay. All results are arithmetic mean and
standard deviation. Before plotting of the regression line and calculation of the correlation coefficient, the data for
AN3661 were excluded because it was used at an extremely high concentration.
https://doi.org/10.1371/journal.ppat.1007315.g010
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intracellular concentration of the benzoxaboroles is reduced through binding to excess CPSF3.
The modest level of resistance may be explained by the fact that CPSF3 normally functions as
part of a complex: we do not know the extent to which CPSF3 can be accumulated indepen-
dently, and its conformation might be influenced by protein-protein interactions.
Over-expression of CPSF3-myc had almost no effect on the EC50 of AN3661. Because of its
low potency, AN3661 was always tested at relatively high (micromolar) concentrations, so this
result is difficult to interpret. However poor binding of AN3661 to CPSF3 is expected, since
the trypanosome protein has residues equivalent to those found in the AN3661 resistant ver-
sion of the Plasmodium falciparum protein (S8 Fig).
Docking studies predict that inhibition of CPSF3 by AN7973 is feasible
To investigate whether AN7973 could interact with CPSF3, we performed induced fit
docking to our comparative model of T. brucei CPSF3 (TbCPSF3). For AN3661, it was
proposed that boron occupies the position of an mRNA substrate phosphate group and
that the ring oxygen, as well as hydroxylations, of the benzoxaborole can interact with the
two active site zinc ions [27]. We applied constraints accordingly when docking AN7973
in the TbCPSF3 active site. In our model, in addition to metal-oxygen interactions and
hydrogen bonding contacts with D67, which stabilize the benzoxaborole binding mode,
the pyrazole ring of AN7973 forms a hydrogen bond with the backbone amide nitrogen of
A406 (S11 Fig). (All residue numbers mentioned correspond to those of the P. falciparum
sequence, PfCPSF3, S8 Fig) The elongated tail of AN7973 lodges in a subpocket that is
largely lined by hydrophobic residues such as F267, P284, F286, L294, A406 and F443.
Notably, the same interaction pattern was observed for both the tetrahedral form of the
compound with a formal negative charge on the boron atom and the trigonal planar neu-
tral variant (S11A and S11B Fig, respectively). The benzoxaborole core of the planar vari-
ant however has a rotated orientation compared to the tetrahedral form, which leads to a
displacement of the loop containing Y408. The results of the docking therefore suggested
that inhibition of TbCPSF3 by AN7973 is feasible.
Discussion
Benzoxaboroles are important drug candidates for both human and ruminant African trypa-
nosomosis. Our results show that AN7973 inhibits mRNA processing in trypanosomes.
Expression of additional CPSF3 increased the EC50 of AN7973, suggesting that AN7973 can
bind to CPSF3. These results suggest that mRNA processing is an important target of AN7973,
which might operate through CPSF3 inhibition. AN7973 also caused metabolite changes
indicative of disturbed methylation, similar to those observed for acoziborole.
When this work was started, AN7973 was under consideration as a candidate for treat-
ment of cattle trypanosomosis, but it was later found to be less effective against T. vivax.
In the available T. vivax genome sequence there is a gap in the CPSF3 open reading frame.
This gap spans N231 in the T. brucei sequence, which is Y in Apicomplexa and humans
and mutated to C in resistant Apicomplexa (S8 Fig). All other CPSF3 residues that are
implicated in AN3661 resistance in Apicomplexa are conserved between T. vivax, T. congo-
lense and T. brucei (S8 Fig). Residues predicted to be in contact with AN7973 in our struc-
tural model of TbCPSF3 were also largely conserved in the T. vivax sequence. Only in the
loop 378–385 (or 403–410 in the P. falciparum numbering) are two valine residues
replaced by isoleucine, which might slightly restrain the space accessible to the compound
in the active site (S8 Fig).
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Our results suggested a mechanistic link between splicing inhibition and accumulation of
specific methylated metabolites (Fig 7B). One hypothesis we had was that the effects on meth-
ylation intermediates could be caused by decreased requirements for cap methylation. How-
ever we found no evidence, either in vivo or in vitro, that SLRNA transcription, capping or
methylation were affected by AN7973. Another hypothesis was that loss of mRNA production
will lead to a selective reduction in the activities of enzymes that have relatively high mRNA
and protein turnover rates, and that these enzymes are required for various aspects of methyla-
tion. This was partially supported by accumulation of methylated amino acids after Actinomy-
cin D treatment.
Strangely, our results revealed no clear structure-function relationships for benzoxaborole
effects on trypanosome viability, metabolites, or splicing. The diversity in structures of com-
pounds that inhibited trypanosome mRNA processing, combined with molecular modelling,
suggests to us that this might be an intrinsic property of the pharmacophore. Nevertheless,
some trends with respect to molecules with the same scaffolds can be noted. For example the
two compounds AN15368 and AN11736 are both L-valinate amide benzoxaboroles [21] and
both showed very little Y structure inhibition (Fig 1, Fig 7). These two compounds also showed
little change in EC50 with overexpression of CPSF3 (Fig 10) suggesting that the L-valinate
amide benzoxaborole series may not act through inhibition of mRNA processing. AN7973 and
AN4169, both of the carboxamide scaffold, also showed similar decreases in Y structure. An
important caveat is that the uptakes and metabolisms of the various compounds are likely to
differ. For example, after 2h incubation, AN3056 and the veterinary drug candidate AN11736
had less effect on processing than did AN7973: but their action might be delayed, since both
are subject to activation within the parasites.
So far, selection of trypanosomes resistant to benzoxaboroles has met very limited success.
Substantial resistance was obtained only for compounds which require intracellular metabolic
activation, and the mutations responsible were in the activating enzymes. For benzoxaboroles
that are probably not metabolised, such as AN7973 and AN2965, only very limited resistance
could be obtained. A priori, one would expect that if these compounds have a single active site
target, selection for resistance should be relatively straightforward. It is however possible that
the necessary mutations are incompatible with function.
Inhibition of mRNA processing was the earliest effect that was seen after AN7973 treatment
and is therefore likely to make a vital contribution to parasite killing. In addition, both docking
studies and results from over-expression identify CPSF3 as a likely target. This raises the possi-
bility that similar modes of action might be seen in oxaboroles under development against
other Kinetoplastids, including Leishmania and Trypanosoma cruzi.
Materials and methods
Ethical statement
All in vivo mouse experiments were carried out in accordance with the strict regulations set
out by the Swiss Federal Veterinary Office, under the ethical approval of the Canton of Basel
City, under license number #2813.
The experimental protocols used for goat studies were approved by the ethics committee
for animal experimentation by the Veterinary Faculty of the University of Las Palmas in Gran
Canaria, Spain on July 21, 2012 with the reference number 240/030/0121-36/2012. The studies
were conducted under the strict guidelines set out by the FELASA for the correct implementa-
tion of animal care and experimentation.
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Tests on cattle were done in accordance with the principles of veterinary good clinical prac-
tice (http://www.vichsec.org/guidelines/pharmaceuticals/pharma-efficacy/good-clinical-
practice.html). The ethical and animal welfare approval number was 00 l-2013/CE-CIRDES.
Compound efficacy studies for T. congolense and T. vivax
Testing of T. congolense in vitro (72 hrs) and T. vivax ex vivo (48 hrs) assays were done as
described in [66]. Testing of T. congolense and T. vivax in vivo in mice was done as described
in [21].
The proof of concept efficacy studies in goats using AN7973 were conducted as previously
described in [67], but established and modified for T. congolense and T. vivax models of infec-
tion. The trials took place from January to May 2013 within the Veterinary Faculty of the Uni-
versity of Las Palmas and the Agricultural farm (Granja Agricola) of the Canarian Island
Government in Arucas, Gran Canaria, Spain. In total, 45 female Canarian goats, weighing
between 12–35 kg and no less than four months old, were purchased from a local dairy farmer
and transported to the study site. The goats were placed in fly-proofed pens and allowed to
acclimatise for two weeks, before being randomly selected and divided into test groups of four.
Goats were experimentally infected intravenously from two highly parasitaemic donor goats,
with 106 and 105 parasites per goat for T. congolense and T. vivax, respectively. AN7973 was
administered intramuscularly accordingly, as either two injections of 10 mg/kg or as a single
bolus dose of 10 mg/kg, on days 7 and 8 post-infection. Thereafter, the parasitaemia was moni-
tored in the goats for up to 100 days post-treatment, after which any aparasitaemic and surviv-
ing goats were considered cured. Relapsed goats were removed immediately from the trial and
humanely euthanized with an intravenous injection of sodium phenobarbital.
The efficacy of AN7973 against T. congolense and T. vivax in cattle was tested as described
in [68]. The studies were conducted in fly-proof facilities and included negative (saline) con-
trols; and the staff were blinded with regard to allocation of animals to treatment groups.
Assessments were made for 100 days post treatment unless animals relapsed sooner.
Trypanosome culture and compound treatment
Bloodstream-form T. brucei brucei 427 Lister strain were cultured in HMI-9 plus 10% foetal
calf serum or CMM [69] plus 20% foetal calf serum at 37˚C, 5% CO2. PCF T. b. brucei were cul-
tured in SDM79 plus 10% foetal calf serum at 28˚C. Compounds were dissolved at 20 mM in
DMSO and aliquoted to avoid excessive freeze-thaw cycles.
EC50s were measured in two different ways. To obtain the EC50s in S1 Fig, compounds
were serially diluted over 24 doubling dilutions in 100 μL culture medium in 96 well opaque
plates from a starting concentration of 100 μM. Bloodstream form trypanosomes were added
at a final density of 2x104/mL (100 μL) and incubated for 48 hours, while procyclic forms were
added at a final density of 2x105/mL and incubated for 72 hours. After incubation, 20 μL of
0.49 mM Resazurin sodium salt in PBS was added to each well and plates were incubated for a
further 24 hours. Plates were read on a BMG FLUOstar OPTIMA microplate reader (BMG
Labtech GmbH, Germany) with λexcitation = 544 nm and λemission = 590 nm.
For the results in S1 Table, sheet 1, column E, bloodstream form trypanosomes were diluted
to 4000/mL in the presence of compounds (diluted in water from DMSO) and incubated for
72h. 3-4h before the end of the incubation, Resazurin (Sigma) was added (final concentration
44 μM). Resazurin fluorescence was measured to assess the number of surviving viable cells
[70, 71]. Each assay was performed with 3 technical and 3 biological replicates.
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For the time to kill assay (S1 Fig, S2 Fig) bloodstream-form T. b. brucei were cultured in 24
well plates in triplicate. Cultures were seeded at 5 x 105/mL and compound was added at
5xEC50. Cells in each well were counted at 2, 4, 6, 8 and 24 hours using a haemocytometer.
For the all assays except the metabolomes shown in Fig 1 and S6 Table, compounds were
used at 10x the 72-h EC50. To allow for variations between drug aliquots, EC50s were measured
prior to every experimental series. The concentrations of compounds used in different experi-
ments are listed in S1 Table and S6 Table.
Cell cycle, protein and Northern blot analyses
For protein analysis, 2-3x106 cells were collected for each sample, resuspended in Laemmli
buffer heated and subjected to SDS-PAGE gel electrophoresis. All assays of macromolecular
biosynthesis and RNA processing were done at densities of less than 2 x 106/mL. Pulse-labeling
was done as described in [72].
Total RNA was extracted from roughly 5x107 cells using peqGold TriFast (peqLab) follow-
ing the manufacturer’s instructions. The RNA was separated on formaldehyde gels and then
blotted on Nytran membranes (GE Healthcare). Following crosslinking and methylene blue
staining (SERVA), the northern blots were hybridized with the appropriate probes. For
mRNA detection, the membranes were incubated with [α-32P]dCTP radioactively labelled
DNA probes (Prime-IT RmT Random Primer Labelling Kit, Stratagene) overnight at 65˚C.
For spliced leader detection, a 39mer oligonucleotide complementary to the spliced leader was
labelled with [γ-32P]ATP using T4 polynucleotide kinase (NEB) and incubated with the mem-
brane overnight at 42˚C. After washing the blot, it was exposed to autoradiography films and
detection was performed with FLA-7000 (GE Healthcare). The images were processed with
ImageJ.
Primer extension assays
Compound treatments were all done at cell densities of about 0.9x106 cells/mL. For each con-
dition, 8-10x107 cells were used. Primer extension was done approximately as described in
[47]; primers were: ACCCCACCTTCCAGATTC for SLRNA (KW01 or CZ6364) and
TGGTTATTTCTCATTTAAGAGG (CZ6491) for U3 snRNA. Both primers and the ladder
were radioactively 5’-end-labelled with [γ-32P]ATP. For extension, 10 μg of RNA was incu-
bated for 5’ at 65˚ with 2 μL of dNTPs (10 mM) and roughly 200 000 counts per minute (cpm)
of the corresponding primer. Afterwards, RNasin (Promega), SuperScript III Reverse Tran-
scriptase (Thermo Fischer), DTT and buffer were added according to the manufacturers
instructions. The mixture was incubated 60’ at 50˚C and then inactivated 15’ at 70˚C. The sam-
ples were run in 35 cm long 6% polyacrylamide gels, dried, and analysed by phosphorimaging.
The images were analysed using Fuji / ImageJ.
In vitro transcription and splicing
In vitro transcription in permeabilised cells was done following the published procedure [48,
61] with minor modifications [73]. Briefly, cells (2.5 x 108/reaction) were permeabilised with
lysolecithin for 1 min on ice, washed, then resuspended in 60 μL transcription buffer. 1 μL of
either AN7973 or DMSO alone were added, and the reaction pre-incubated at 28˚C for 2 min.
After addition of 100 μL transcription cocktail containing 1 μL of either AN7973 or DMSO,
the reaction was allowed to proceed for 10 min at 28˚C. The permeabilised cells were pelleted
(45 sec) and resuspended in 1 mL of TriFast. After the first phase separation, the aqueous frac-
tion was re-extracted with phenol to remove residual protein; this was necessary to obtain
good separation during gel electrophoresis. The final RNA volume was 20 μL. 10 μL of each
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reaction were separated on a 7% polyadcrylamide/urea gel and the products were detected by
phosphorimaging with low molecular weight DNA markers (New England Biolabs).
Genomic sequence analysis
For genomic DNA sequencing, libraries were prepared at the Cell Networks Deep Sequencing
Core Facility (University of Heidelberg) and subjected to paired-end MiSeq (Illumina) at
EMBL. The quality of sequencing was evaluated with FastQC and the reads were trimmed
using Trimmomatic. The output was aligned to the T. b. brucei TREU927 genome (version
9.0) using bowtie2. Results are available in ArrayExpress under accession number E-MTAB-
6307. The Picard option AddOrReplaceReadGroups was used to create a valid .bam file to
then be piped into GATK for obtaining, as output, .vcf files containing SNP and indel informa-
tion. SnpSift filtered the features of interest, excluding for example synonymous mutations
and intergenic regions. Identified variations from all cell lines were pooled to look for muta-
tions found in all strains compared to the wild type, and in addition, reads from each strain
were processed separately to find all the mutated genes. The lists were then compared. The
genes taken into consideration were identified with annotation and categories from the Clay-
ton lab in-house annotation list. Based on these annotations, the genes were filtered in Excel,
where highly repetitive genes were excluded from the analysis. At first, variant surface glyco-
proteins (VSG), expression site-associated genes (ESAG), receptor-type adenylate cyclase
GRESAG, UDP-Gal or UDP-GlcNAc-dependent glycosyltransferases and pseudogenes were
removed. In the case of non-homozygous mutations, the genes were further selected filtering
out other repetitive genes such as leucine-rich repeat proteins (LRRP), various invariant sur-
face glycoproteins (ISG), nucleoside transporters (TbNT) and retrotransposon hot spot (RHS)
proteins. The list of gene IDs was compared with their translation level based on ribosome pro-
files [74, 75] and genes with values below 10 (non-translated) were excluded from the analysis.
Metabolomics
For all assays at 5x EC50, bloodstream-form T. b. brucei were inoculated into medium at 1 x
106/mL (for a six or eight hour incubation) or 2 x 105/mL (for a 24 hour incubation) and com-
pounds were added. Cells were incubated with compounds under normal growth conditions.
At the desired time point, 1 x 108 cells were taken and cooled rapidly in a dry-ice ethanol bath
to 4˚C. Samples were centrifuged at 1250 g twice to remove all medium before 200 μL chloro-
form:methanol:water (1:2:1) were added. Extracts were shaken for one hour at max speed
before cell debris was removed by centrifugation at 16,000 g. Metabolite extracts were stored at
-80˚C under argon gas.
Mass spectrometry–Metabolite samples were defrosted and run on a pHILIC column cou-
pled to an Orbitrap mass spectrometer as previously described [76]. In batch 1 an Orbitrap
Exactive (Thermo Scientific) was used with settings including mass range: 70–1400, a lock
mass of 74.0964, capillary: 40V, Tube lens: 70V, Skimmer: 20V, Gate lens: 6.75V and C-trap
RF: 700V. In batch 2 an Orbitrap QExactive (Thermo Scientific) was used with settings includ-
ing mass range: 70–1050, lock masses of 74.0964 and 88.0757, S-lens: 25V, Skimmer: 15V,
Gate lens: 5.88V and C-trap RF: 700V. For fragmentation analysis an MS2 isolation window of
4 m/z, an intensity threshold of 3.3e5 and dynamic exclusion of 10 seconds were used.
Metabolites were putatively annotated using IDEOM software [77] before verification of
annotations using mass, retention time, isotope distribution and fragmentation pattern. Xcali-
bur (Thermo) was used to explore the raw data, MzCloud (mzcloud.org) was used to match
fragments to database spectra. Metabolite analysis was done using four biological replicates
per condition and cell line. Relative metabolite levels were based on raw peak height relative to
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the average raw peak height of untreated cells. Lists of metabolites were mapped on metabolic
pathways using Pathos (http://motif.gla.ac.uk/Pathos/). Intersections between samples were
found using bioVenn (http://www.cmbi.ru.nl/cdd/biovenn/). (http://www.cmbi.ru.nl/cdd/
biovenn/). Metabolite identities are consistent with standards from the Metabolomics Stan-
dards Initiative and evidence for each identity is shown in S6 Table.
YFP-DHH1 and expression of myc-tagged proteins
For over-expression of C-terminally myc-tagged proteins, the open reading frames encoding
proteins of interest were amplified by PCR from genomic DNA, and cloned into pRPa-6xmyc
[78]. After transfection, cells were selected and expression of myc-tagged protein was induced
overnight with 100 ng/mL tetracycline.
The plasmid for creation of cells expressing YFP-DHH1 [59] was a kind gift from Susanne
Kra¨mer (University of Wu¨rzburg). It was transfected into bloodstream-form trypanosomes
and two stable cell lines expressing the protein were selected. Trypanosomes (maximum den-
sity less than 1 million/mL in 10 mL) were treated for 30 min with 2 μg/mL Sinefungin, or for
1-2h with compounds at 10x EC50. After collection (5 min 1000g) and washing in PBS cells
were resuspended in 20 μL PBS. 500 μL of 4% paraformaldehyde solution in PBS was added,
cells were incubated without shaking for 18 min, washed 3x with PBS, then distributed onto
poly-lysine coated chamber glass slides (all cells divided in two chambers) and left at 4˚C over
night. The PBS was then removed and cells were permeabilised using 0.2% Triton X-100 (w/v)
in PBS, with shaking at room temperature for 20 min. After a further 3 washes, slides were
incubate at room temperature with 200 ng/mL DAPI in PBS (15 min shaking), washed twice
more, air-dried, embedded and covered for microscopy.
Slides were viewed and the images captured with Olympus IX81 microscope. The 100x oil
objective was used. Digital imaging was done with ORCA-R2 digital CCD camera C10600
(Hamamatsu) and using the xcellence rt software. Bright field images were taken using differ-
ential interference contrast (DIC), Exposure time 30 ms, Lamp 4.0. Fluorescent images were
made using DAPI and YFP filters. They were taken as Z-stacks, 30–40 images in a 8 μm thick
layer, Exposure time 40 ms, Light intensity 100%, and afterwards they were deconvoluted
(Numerical aperture 1.45, Wiener filter, Sub-Volume Overlap 20, Spherical Aberration Detec-
tion Accurate).
The fluorescence images were processed using ImageJ. For YFP and DAPI channels, layers
containing signals ere selected, then the projection of maximum intensity of the deconvoluted
stack was used. The images were saved in an 8-bit range then overlayed with DAPI in cyan
and YFP as magenta. The colour balance was then adjusted with variable maxima for DAPI/
cyan, but a set maximum of 80 for YFP/magenta.
After initial assessment after AN7973 and Sinefungin treatment, three independent experi-
mental series, each including a negative control, were processed, and the images were read
blinded. Cells were classified as having nuclear periphery granules if there were at least four
strong granules on top of, or within one granule diameter of, the nucleus. Cells were classified
as "strong" if nearly all granules were around the nucleus, and "possible" if there were several
granules in other positions as well. For granule counts, only structures with at least four adja-
cent pixels at maximum intensity were considered.
Homology modeling. Models of Trypanosoma brucei (TbCPSF3) and, for comparison,
Plasmodium falciparum CPSF3 (PfCPSF3), were built with the Advanced Homology Modeling
routine of Schro¨dinger Maestro [79]. A BLAST search [80] was performed and the crystal
structure of human CPSF73 with PDB ID 2i7v was chosen as the template for both models
(Resolution 2.1 Å; sequence identity 56% and 43% for TbCPSF3 and PfCPSF3, respectively).
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Globally conserved residues in the beta-CASP family were identified from a multiple sequence
alignment making use of the Pfam database [81]. Conformations of the globally conserved res-
idues E293, L298 and G386 (P. falciparum numbering) were retained similar to the template
structure without further modification. Alignment of template and query sequences was per-
formed by ClustalW. A knowledge-based model, including the template structure-Zn2+ ions,
was built and subjected to protein preparation without further loop refinement. Addition of
hydrogen atoms and bond order assignment were done with the Protein Preparation Wizard
of Maestro [79]. Amino acid protonation states at pH 7.0 were determined using PROPKA
[82]. Next, the hydrogen bonding network was optimized and models were subjected to a
restrained energy minimization using the OPLS3 force field allowing for a maximum heavy
atom RMSD of 0.3 Å [83]. For validation of the structural models, PROCHECK and QMEAN
analyses were performed [84]. Results are summarized in S9 Table. The analysis demonstrates
that the models are of reasonable quality and that, in particular, the binding site close to the
zinc ions, as the main region of interest, showed good local quality (S12 Fig).
Normal mode analysis. The NOMAD-Ref webserver was used to calculate normal modes
for the modeled structure of TbCPSF3 using an elastic network model (ENM) and considering
all atoms [85]. 16 modes were calculated with a distance weight parameter of 5.0 Å for the elas-
tic constant, an ENM cutoff of 10 Å and an average RMSD of 1.0 Å in output trajectories,
using the automatic method.
Compound preparation and docking studies. AN7973 was considered in the neutral, tri-
gonal planar form, and as the conjugate Lewis base with a formal negative charge on the boron
and tetrahedral geometry [8, 86, 87]. Since a non-substituted benzoxaborole has a pKa of 7.3, a
non-substituted 3,3-dimethyl benzoxaborole a pKa of 8.3 and, depending on nature and posi-
tion of a substitution on the benzene ring, further shifts towards a more basic or acidic pKa
were possible, the preferred geometry of AN7973 was unclear [86]. Moreover, a possible influ-
ence of the positively charged metal ions in the protein binding site on the compound state
could not be excluded.
Docking studies were performed for the models of TbCPSF3 and PfCPSF3. We used the
Induced Fit Docking protocol of Schro¨dinger, since the template structure for the homology
modeling did not have any bound ligands and it is thus likely that ligand binding requires
some reorganization in the binding site [88–90]. The standard protocol to produce up to 20
receptor-ligand complexes per ligand and the OPLS3 force field were chosen [83]. Grids were
centered on Y408 or the respective equivalent (PfCPSF3 numbering) and had a size of 26 Å in
x-, y- and z-directions. Docking results were constrained by requiring a ligand contact with
each of the two zinc ions: any acceptor atom of the ligand within a distance no greater than the
sum of the van-der-Waals radii of zinc and the respective ligand atom plus an additional 0.4 Å
satisfied the constraint. Ligand ring conformations were sampled and discarded if their energy
was more than 2.5 kcal/mol higher than the conformation lowest in energy. Non-planar con-
formations of amide bonds were penalized and the torsional potential around bonds which
should adopt a planar geometry was increased to lessen the likelihood of observing non-planar
geometries. In the initial Glide docking step, the van-der-Waals radii of both the receptor and
ligand atoms were scaled by a factor of 0.50 to mimic some flexibility. A maximum number of
20 poses per ligand was collected at this stage and subjected to a Prime refinement. Residues
within 5 Å of the initial ligand pose were refined and side chain optimization was performed.
Finally, redocking was carried out using the standard precision protocol to dock the ligands
into all refined protein structures within 30 kcal/mol of the best structure and the top 20 struc-
tures overall.
The trypanocidal benzoxaborole AN7973 inhibits trypanosome mRNA processing
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007315 September 25, 2018 24 / 33
Supporting information
S1 Table. EC50s and compound concentrations used in different experimental series. For a
detailed legend see the top sheet.
(XLSX)
S2 Table. Summary of copy number changes, single nucleotide polymorphisms (snps) and
insertions and deletions (indels) in cells with weak resistance to AN7973. A description of
the experiments is on sheet 1.
(XLSX)
S3 Table. Details of snps and indels in cells with weak resistance to AN7973. For a detailed
legend see the top sheet.
(XLSX)
S4 Table. Details of copy number variations in cells with weak resistance to AN7973. For a
detailed legend see the top sheet.
(XLSX)
S5 Table. Metabolite changes after treatment of wild-type and mildly resistant cells with
AN7973 for 5h. For a detailed legend see the top sheet.
(XLSX)
S6 Table. Levels of chosen metabolites after treatment with different compounds. For a
detailed legend see the top sheet.
(XLSX)
S7 Table. Metabolomic effects from treating trypanosomes with Actinomycin D or
AN5568 for 5h.
(XLSX)
S8 Table. EC50s of various benzoxaboroles in cells with and without additional CPSF3
expression.
(XLSX)
S9 Table. Global validation of homology models. Details are in the Table.
(XLSX)
S1 Fig. Statistical analysis of results in Fig 3. A: Results for an initial experiment in which the
level of Y structure was quantified relative to SLRNA. S 30’ is the control value after incubation
with Sinefungin for 30 min.
B—F: 95% confidence intervals of mean differences between Y structure quantifications for
panel A and for Fig 3E–3H. The intervals were calculated using Dunnet’s multiple compari-
sons test. In each case the calculation is done for the comparison between no treatment and
the treatment indicated. The higher the difference, the lower the chance that the values were
not significantly different. A value of 0 indicates a 5% chance that differences were not signifi-
cant. Sinefungin values are for the difference between no drug and 30 min with Sinefungin.
(PDF)
S2 Fig. A. Growth curves of bloodstream-form T. brucei in the presence and absence of
benzoxaboroles.
(PDF)
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S3 Fig. Time-to-kill assays for benzoxaboroles—like S1 Fig but with more compounds and
without the untreated control.
(PDF)
S4 Fig. Effects of benzoxaboroles on Y structure levels. A. Time course of effects of AN7973,
AN3967, AN5827 and AN11736 in bloodstream forms (Experiment 2 in Fig 7). Sinefungin
treatment was for 30 min.
B, C: effect of AN7973 in procyclic forms.
(PDF)
S5 Fig. Results for three separate experiments (A, B and C) in which the location of
YFP-DHH1 was analysed. The average percentages of cells with clear (dark blue) or possible
(pale blue) peri-nuclear granules are plotted as bars, with the average numbers of large gran-
ules (at least 4 contiguous pixels at maximum intensity) anywhere in the cell displayed as black
spots. The dotted line corresponds to the negative control.
(PDF)
S6 Fig. YFP-DHH1 localization after treatment with different benzoxaboroles. These are
not "typical" images; instead, fields in which nuclear periphery granules were present have
been chosen. Some (but not all) examples of peri-nuclear granule patterns are indicated by
arrows. Compounds used are shown on each image. For AN7973 examples from the three dif-
ferent experiments are shown. The key is on the bottom left.
(TIF)
S7 Fig. YFP-DHH1 localization after treatment with different benzoxaboroles. These are
not "typical" images; instead, fields in which nuclear periphery granules were present have
been chosen. Compounds used are indicated and the key is as in S6 Fig. The control image in
this case had brighter YFP fluorescence, for unknown reasons.
(TIF)
S8 Fig. Sequences of CPSF3 from T. brucei (TREU927), T. congolense, T. vivax, Plasmodium
falciparum and Homo sapiens. Only the conserved region is shown. Black-highlighted resi-
dues are identical in at least four sequences and blue ones indicate conservative replacements.
For key to symbols and numbers see the bottom of the Fig. The gap in the T. vivax sequence is
present because of a gap in the genome assembly.
(PDF)
S9 Fig. Domain annotations, residues linked to resistance mutations in P. falciparum and
T. gondii mapped onto a structural model of TbCPSF3 and exemplary results of the normal
mode analysis for the TbCPSF3 structure. A. Conserved domains found in CPSF3 adapted
from the Pfam domain annotations. RMMBL: Zn-dependent metallo-hydrolase RNA specific-
ity domain; CPSF73-100_C: C-terminal conserved region of the pre-mRNA 3’-end-processing
of the polyadenylation factor CPSF-73/CPSF-100 proteins. As indicated, this C-terminal
domain is not present in the structural model.
B. Homology model of TbCPSF3 in cartoon representation colored according to the domain
annotations in (A). Residues associated with resistance to benzoxaboroles are highlighted as
sticks; the residue numbering corresponds to the P. falciparum sequence. Grey dots indicate
the predicted binding pocket for AN7973 for reference.
C. Overlay of two snapshots from the first (slowest) mode obtained by normal mode analysis
of the TbCPSF3 model structure. The protein is shown in ribbon representation and colored
according to the domain annotations in (A). The modes show a general relative rotational
breathing motion of the domains as indicated by the arrows. Two important residues lining
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the interdomain contact region, N252 and Y408 (P. falciparum numbering) are shown as red
sticks for reference.
(PNG)
S10 Fig. Details of EC50 results in cells with and without CPSF3-myc expression. (A)
Induced expression of Myc-tagged RBSR4 and U2AF35.
(B) IC50 measurements in cells with tetracycline-inducible expression of myc-CPFS3.
(PDF)
S11 Fig. Induced fit docking results for AN7973 in the active site of TbCPSF3. AN7973
(cyan sticks) was docked in the negatively charged form (A, tetrahedral geometry) and the
neutral form (B, trigonal planar geometry). In both cases, the top scoring poses with Glide
docking scores of -9.3 kcal/mol and -8.4 kcal/mol, respectively, are shown. For the tetrahedral
geometry, in total, two poses with an average docking score of -9.0±0.4 kcal/mol and for the
planar geometry, three poses with an average docking score of -6.9±1.4 kcal/mol were
obtained. The TbCPSF3 homology model is shown in grey cartoon representation with impor-
tant interacting residues highlighted as sticks and the zinc ions as grey spheres. Dashed lines
indicate metal-coordination bonds (grey), metal-ligand interactions (black) and hydrogen
bonds to the ligand (purple). The residue numbers correspond to the Plasmodium falciparum
CPSF3 sequence.
(PNG)
S12 Fig. Local quality estimate by QMEAN score mapped to the protein structures of
hCPSF73 (template) and the homology models of TbCPSF3 and PfCPSF3. Proteins are
shown in cartoon representation. The location of the binding site is indicated by the zinc ions,
shown as grey spheres. Local quality estimates are color coded from red (worst) to blue (best).
A. human template structure 2i7v, hCPSF73; B. TbCPSF3; C. PfCPSF3.
(PNG)
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